Dose adjustment in renal impairment: Response from the British National FormularyBMJ 2005; 331 doi: https://doi.org/10.1136/bmj.331.7511.292 (Published 28 July 2005) Cite this as: BMJ 2005;331:292
- Dinesh K Mehta, executive editor (firstname.lastname@example.org)
- British National Formulary, Royal Pharmaceutical Society of Great Britain, London SE1 7JN
EDITOR—Vidal et al are rightly concerned that information on dose adjustment is not as well supported by evidence as our knowledge about the effectiveness of modern interventions (p 263). 1 But, as they have found, the lack of robust data to guide clinicians on the precautions to take when using drugs is woeful. Therefore, their conclusions come as no surprise to compilers of drug information.
Because there are few accessible studies on dose adjustment in renal impairment, the British National Formulary (BNF) has to rely on summaries of product characteristics, which reflect data submitted for gaining marketing …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial